Back to Directory Franklin Yates Email franklin.yates@nih.gov Institution NICHD Title Doctor Request an Update Affiliated Studies IMPAACT 2041: Phase IV Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir (GLE/PIB) in People with Hepatitis C During Pregnancy and Postpartum DAIDS Number TBD Research Area Complications & Comorbidities IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Treatment Study Status Pending IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Treatment Study Status Enrolling
IMPAACT 2041: Phase IV Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir (GLE/PIB) in People with Hepatitis C During Pregnancy and Postpartum DAIDS Number TBD Research Area Complications & Comorbidities
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Treatment Study Status Pending
